Amarna Therapeutics

About Amarna Therapeutics

Amarna Therapeutics is a privately held, pre-clinical biotech company developing transformative, potentially curative gene therapies for a range of both rare and prevalent diseases.

The company is pioneering the development of gene therapies based on simian virus 40 (SV40), a macaque polyoma virus to which humans are immunologically naïve. Amarna has created a proprietary production cell line (SuperVero™) that, for the first time, makes it possible to produce SV40-derived vectors suitable for therapeutic use.

Combining SuperVero™ with its genetically engineered SVec viral vector, the company’s fully-integrated gene therapy platform is truly unique in its intrinsic capability to deliver transgenes without eliciting immune responses to the vector nor to the transgene product.

Leveraging this ‘natural’ non-immunogenicity feature of its gene delivery system in humans, Amarna is developing a broad pipeline of safe, effective and durable gene therapies focused on genetic disorders, autoimmune diseases and chronic inflammation.

Founded in 2008, Amarna’s head office is based in Leiden Bio Science Park, the Netherlands, with a research subsidiary located in Seville, Spain.

Address

• Headquarters

  J.H. Oortweg 212333CH LeidenZuid-Holland, Netherlands

Team by function

Based on 11 public job profiles as of 4 September 2026.

• Research / R&D3
• Operations2
• Other / Unclassifiable2
• Executive / C-Suite1
• Finance / Accounting1
• Founder / Owner1
• Healthcare / Medical1